Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer.
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.